Immuno-Oncology | Specialty

Long-Term Data Show Improved CR Rates for Cosibelimab in Advanced CSCC

July 28th 2023

Long-term data demonstrated that treatment with cosibelimab improved complete response rates over time in patients with locally advanced or metastatic cutaneous squamous cell carcinoma in a phase 1 trial.

mRNA-4157 Plus Pembrolizumab Under Further Investigation in Phase 3 Trial in High-Risk Melanoma

July 26th 2023

The combination of mRNA-4157 and pembrolizumab will be further evaluated as an adjuvant treatment option for patients with resected, high-risk, stage IIB to IV melanoma in the phase 3 V940-001 trial.

First-Line Rivoceranib Plus Camrelizumab Improves Survival in Unresectable HCC

July 25th 2023

Treatment with the combination of rivoceranib and camrelizumab led to a statistically significant and clinically meaningful benefit in progression-free survival and overall survival compared with sorafenib in previously untreated patients with unresectable hepatocellular carcinoma.

Evaluating Toxicities of Antineoplastic Drug Therapeutics: Is It Time for a Critical Review?

July 24th 2023

An evaluation of the utility of a cancer therapeutic in a clinical trial is determined through metrics that define 2 distinctive features of an antineoplastic strategy: efficacy and toxicity. Although that may be an oversimplification, the aim of such therapy is to improve clinical outcomes.

Fianlimab Plus Cemiplimab Produces Durable Responses in Advanced Melanoma

July 24th 2023

Omid Hamid, MD, discusses the key efficacy and safety findings for the combination of fianlimab plus cemiplimab in patients with advanced melanoma.

CHMP Supports Approval of Pembrolizumab Plus Trastuzumab/Chemotherapy for HER2+, PD-L1+ Advanced Gastric/GEJ Cancer

July 21st 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of pembrolizumab plus trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the frontline treatment of patients with advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumors have a PD-L1 combined positive score of at least 1.

ENB-003 Plus Pembrolizumab Elicits Safety, Activity in Ovarian Cancer and Other Advanced, Refractory Solid Tumors

July 20th 2023

Treatment with the combination of ENB-003 and pembrolizumab was well tolerated and produced preliminary signs of clinical activity in patients with platinum-refractory or -resistant, microsatellite stable ovarian cancer, and those with other advanced refractory solid tumors.

Tislelizumab Plus Bevacizumab/Chemo Demonstrates Early Efficacy in Cervical Cancer

July 20th 2023

The addition of the PD-L1 inhibitor tislelizumab to standard bevacizumab and platinum-doublet chemotherapy in the first-line setting prolonged progression-free survival, produced encouraging responses, and was well tolerated in patients with cervical cancer.

Pembrolizumab Plus Chemoradiotherapy Meets PFS End Point in High-Risk Locally Advanced Cervical Cancer

July 19th 2023

The addition of pembrolizumab to external beam radiotherapy and concurrent chemotherapy, followed by brachytherapy, improved progression-free survival vs concurrent chemoradiotherapy alone in newly diagnosed patients with high-risk locally advanced cervical cancer.

Setanaxib Plus Pembrolizumab Elicits PFS Benefit in Recurrent or Metastatic HNSCC

July 18th 2023

The combination of the NOX1/4 inhibitor setanaxib and pembrolizumab produced progression-free survival benefits compared with placebo plus pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Immuno-Oncology Approaches Continue to Advance Across Gynecologic Cancers

July 11th 2023

Michael J. Birrer, MD, PhD, highlights the effect of improved molecular characterization in endometrial cancer, the clinical significance of the KEYNOTE-775 trial, and recent changes in the frontline treatment landscape in advanced endometrial cancer.

ONC-392/BNT316 Elicits Clinical Activity in Checkpoint Inhibitor–Resistant NSCLC

July 2nd 2023

ONC-392/BNT316 demonstrated early signs of antitumor activity and manageable safety in patients with metastatic, PD-(L)1–resistant non–small cell lung cancer.

Adjuvant Pembrolizumab Continues to Provide Survival Benefit in Stage IIB/C Melanoma

June 30th 2023

Pembrolizumab led to sustained improvements in recurrence-free survival and distant metastasis–free survival vs placebo as adjuvant therapy in patients with resected stage IIB or IIC melanoma

Neoadjuvant Nivolumab/Chemo Wins EU Approval for Resectable PD-L1+ NSCLC

June 29th 2023

The European Commission has approved nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of patients with resectable non–small cell lung cancer at high risk of recurrence with tumor cell PD-L1 expression of at least 1%.

FDA Grants Fast Track Status to Quaratusugene Ozeplasmid Plus Atezolizumab in ES-SCLC

June 29th 2023

The FDA has granted fast track designation to the combination of quaratusugene ozeplasmid and atezolizumab as maintenance therapy in patients with extensive-stage small cell lung cancer whose disease did not progress after receiving initial standard treatment with atezolizumab and chemotherapy.

Galinpepimut-S Plus Nivolumab Provides Survival Benefits With Acceptable Safety in Mesothelioma

June 28th 2023

The combination of galinpepimut-S and nivolumab provided positive survival outcomes with an acceptable safety profile in patients with malignant pleural mesothelioma who were refractory to or relapsed after at least 1 line of standard treatment.

Examining LIFU–Aided Liquid Biopsy in Glioblastoma: Raising the Bar With the LIMITLESS Trial

June 27th 2023

In this fourth episode of OncChats: Examining LIFU–Aided Liquid Biopsy in Glioblastoma, Manmeet Singh Ahluwalia, MD, MBA, FASCO, and Michael W. McDermott, MD, discuss the key objectives of the phase 3 LIMITLESS study (NCT05317858) examining low-intensity focused ultrasound with immunotherapy and chemotherapy in patients with lung cancer and brain metastases.

Camrelizumab Plus Famitinib Demonstrates Early Antitumor Activity in Advanced Melanoma

June 25th 2023

Camrelizumab combined with famitinib elicited responses and was well tolerated in patients with advanced melanoma previously exposed to an immune checkpoint inhibitor regimen.

Favezelimab Plus Pembrolizumab Continues to Elicit Antitumor Activity in R/R Classical Hodgkin Lymphoma

June 21st 2023

The combination of favezelimab and pembrolizumab continued to demonstrate a manageable safety profile and antitumor activity in patients with relapsed/refractory classical Hodgkin lymphoma, irrespective of whether they received prior anti–PD-1 therapy.

Determining the Optimal Use of Adjuvant Immunotherapy in Renal Cell Carcinoma

June 19th 2023

Kidney and renal pelvis cancers are one of the 10 most common new malignant diagnoses in both men and women in the United States, with an estimated 52,360 new cases in men and 29,440 new cases in women per year.